New coronavirus infection (COVID-19): from the dermatologist’s view

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Recently published data on the pathogenesis and cutaneous manifestations of a new coronavirus infection (COVID-19) are presented. The most described lesions are urticarial, papulo-vesicular, erythematous rash, purpura, livedo-angiitis, as well as chilblains. Eruptions mainly appear together with main COVID-19 symptoms or a few days later. The treatment of new coronavirus infection may lead to a quick regression of skin lesions along with improvement of the general state of the patient. The review also provides data on the fact that COVID-19 patients with severe psoriasis and atopic dermatitis receiving biologic therapy (guselkumab, ustekinumab, adalimumab, secukinumab, ixekizumab, etanercept, dupilumab) and phosphodiesterase-4 inhibitors experience mild or asymptomatic COVID-19. Moreover, such patients do not develop cutaneous manifestations of COVID-19. The specific COVID-19 treatment has not been developed yet. We think that these findings might provide better understanding of mechanisms of action of biologic drugs in COVID-19.


Full Text

Restricted Access

About the authors

Olga Yu. Olisova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989
Scopus Author ID: 55829948600
ResearcherId: AAL-7600-2020

Russian Federation, 8-2, Trubetskaya street, Moscow, 119992

MD, PhD, Professor

Ekaterina M. Anpilogova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: truelass@hotmail.com
ORCID iD: 0000-0001-9478-5838
ResearcherId: AAG-7260-2019

Russian Federation, 8-2, Trubetskaya street, Moscow, 119992

PhD Student

References

  1. Временные методические рекомендации «Профилактика диагностика и лечение новой коронавирусной инфекции (COVID19)» Министерства здравоохранения Российской Федерации (вер. 6 от 24.04.2020). Available from: https://www.rosminzdrav.ru/ministry/med_covid19.
  2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak as sociated with a new coronavirus of probable bat origin. Nature. 2020;259:270–273.
  3. Ji W, Wang W, Zhao X, Zai J, Li X. Cross-species transmission of the newly identified coronavirus 2019- nCoV. J. Med. Virol. 2020; 92:433–440.
  4. Did pangolins spread the China coronavirus to people? Available from: https://www.nature.com/articles/d41586-020-00364-2#ref-CR1 (accessed 28.02.2020).
  5. Liu P, Chen W, Chen JP. 2019. Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica). Viruses 11. pii: E979.
  6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet. 2020;Mar28;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
  7. Bilinska K, Jakubowska P, VON Bartheld CS, Butowt R. Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age. ACS Chem Neurosci. 2020. May 7. doi: 10.1021/acschemneuro.0c00210. [Epub ahead of print]
  8. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status. Military Medical Research. 2020;7:11.
  9. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis. 2020.Apr;10(2):102–108. doi: 10.1016/j.jpha.2020.03.001.
  10. Кубанов А.А., Дерябин Д.Г. Новый взгляд на патогенез COVID-19: заболевание является генерализованным вирусным васкулитом, а возникающее при этом поражение легочной ткани ― вариантом ангиогенного отека легкого // Вестник РАМН. — 2020. — № 75 (2). — С. 115-117. [Kubanov AA, Deryabin DG. A New Look at the COVID-19 Pathogenesis: the Disease is a Generalized Viral Vasculitis, and the Lung Tissue Damage is a Variant of Angiogenic Pulmonary Edema. Annals of the Russian Academy of Medical Sciences. 2020;75(2):115–117. (in Russ.)]. doi: 10.15690/vramn1347.
  11. Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity (Silver Spring). 2020. Apr 27. doi: 10.1002/oby.22856. [Epub ahead of print]
  12. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020. May. doi: 10.1016/j.jaut.2020.102433.
  13. Lucas JM, Heinlein C, Kim T, et al. The androgen-regulatedprotease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4(11):1310–1325.
  14. National Institutes of Health. TMPRSS2 transmembrane serine protease 2 [Homo sapiens (human)] Gene ID: 7113. Updated March 13, 2020. Available at: https://www.ncbi.nlm.nih.gov/gene/7113 (аccessed: 02.04.2020).
  15. Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020. Apr 10. pii: S0190-9622(20)30608-3. doi: 10.1016/j.jaad.2020.04.032. [Epub ahead of print]
  16. Murrell DF, Murase JE. The Dermatologist’s Perspective: Why is COVID-19 mortality lower in females than males? International Journal of Women’s Dermatology. 2020. https://doi.org/10.1016/j.ijwd.2020.04.011.
  17. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/map.html. Published May 20, 2020 (аccessed: 20.05.2020).
  18. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020. Mar 26. doi: 10.1111/jdv.16387. [Epub ahead of print]
  19. Tammaro A, Adebanjo G, Parisella F, et al. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16530. [Epub ahead of print]
  20. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. Journal of the American Academy of Dermatology. 2020. doi: https://doi.org/10.1016/j.jaad.2020.04.044.
  21. Bouaziz JD, Duong T, Jachiet M, et al. Vascular skin symptoms in COVID-19: a french observational study. J Eur Acad Dermatol Venereol. 2020. Apr 27. doi: 10.1111/jdv.16544. [Epub ahead of print]
  22. Moreno AR, Villa E, Moreno AV, et al. Cutaneous manifestation of COVID-19 in images: a case report. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16531. [Epub ahead of print]
  23. Estebanez A, Pérez-Santiago L, Silva E, et al. Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol. 2020. Apr 15. doi: 10.1111/jdv.16474.
  24. Van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16523. [Epub ahead of print]
  25. Gianotti R, Veraldi S, Recalcati S, et al. Cutaneous Clinico-Pathological Findings in Three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy. Acta Derm Venereol. 2020. Apr 23;100(8): adv00124. doi: 10.2340/00015555-3490.
  26. Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. May 2. doi: 10.1111/jdv.16579. [Epub ahead of print]
  27. Janah H, Zinebi A, Elbenaye J. Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2. J Eur Acad Dermatol Venereol. 2020. May 9. doi: 10.1111/jdv.16623. [Epub ahead of print]
  28. Robustelli E, Vezzoli P, Carugno A, Raponi F, Gianatti A, Rongioletti F, Sena P. Acute generalized exanthematous pustulosis with erythema multiforme‐like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID‐19). doi: https://doi.org/10.1111/jdv.16613
  29. Quintana-Castanedo L, Feito-Rodríguez M, Valero-López I. Urticarial exanthem as early diagnostic clue for COVID-19 infection. JAAD Case Rep. 2020. Apr 29. doi: 10.1016/j.jdcr.2020.04.026. [Epub ahead of print]
  30. Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, et al. Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol. 2020. Apr 15. doi: 10.1111/jdv.16470. [Epub ahead of print]
  31. Henry D, Ackerman M, Sancelme E, et al. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. Apr 15. doi: 10.1111/jdv.16472. [Epub ahead of print]
  32. Van Damme C, Berlingin E, Saussez S, et al. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16523. [Epub ahead of print]
  33. Gunawan CA, Widysanto A. Urticarial eruption in Coronavirus Disease 2019 (COVID-19) infection: a case report in Tangerang, Indonesia. J Eur Acad Dermatol Venereol. 2020. May 9. doi: 10.1111/jdv.16622. [Epub ahead of print]
  34. Amatore F, Macagno N, Mailhe M, et al. SARS-CoV-2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16528. [Epub ahead of print]
  35. De Masson A, Bouaziz J-D, Sulimovic L, et al. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. Journal of the American Academy of Dermatology. 2020. doi: https://doi.org/10.1016/j.jaad.2020.04.161.
  36. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16526. [Epub ahead of print]
  37. Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the Time of COVID-19. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16533. [Epub ahead of print]
  38. Andina D, Noguera-Morel L, Bascuas-Arribas M, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020. May 9. doi: 10.1111/pde.14215. [Epub ahead of print]
  39. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020. May; 82(5):1217–1218. doi: 10.1016/j.jaad.2020.03.031. [Epub 2020 Mar 19]
  40. Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020 Mar; 11:e13298.
  41. Bardazzi F, Loi C, Sacchelli L, et al. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. [Published online ahead of print, 2020 Apr 6]. J Dermatolog Treat. 2020;1–2.
  42. Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol. 2020. Apr 15. doi: 10.1111/jdv.16468. [Epub ahead of print]
  43. Benhadou F, Del Marmol V. Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient. J Eur Acad Dermatol Venereol. 2020. May 7. doi: 10.1111/jdv.16590. [Epub ahead of print]
  44. Conti A, Lasagni C, Bigi L, et al. Pellacani Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs. J Eur Acad Dermatol Venereol. 2020. May 7. doi: 10.1111/jdv.16587. [Epub ahead of print]
  45. Di Lernia V, Bombonato C, Motolese A. COVID-19 in an elderly patient treated with secukinumab. Dermatol Ther. 2020. May; 13:e13580. doi: 10.1111/dth.13580. [Epub ahead of print]
  46. Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: a high-epidemic area experience — Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020. May 6. pii: S0190–9622(20)30819-7. doi: 10.1016/j.jaad.2020.04.165. [Epub ahead of print]
  47. Balestri R, Rech G, Girardelli CR. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. J Eur Acad Dermatol Venereol. 2020. May 2. doi: 10.1111/jdv.16571. [Epub ahead of print]
  48. Gisondi P, Facheris P, Dapavo P, et al. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. Br J Dermatol. 2020. Apr 28. doi: 10.1111/bjd.19158. [Epub ahead of print]
  49. Mugheddu C, Pizzatti L, Sanna S, et al. COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management. J Eur Acad Dermatol Venereol. 2020. May 9. doi: 10.1111/jdv.16625. [Epub ahead of print]
  50. Caroppo F, Biolo G, Belloni Fortina A. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab. J Eur Acad Dermatol Venereol. 2020. May 9. doi: 10.1111/jdv.16619. [Epub ahead of print]
  51. Ferrucci S, Romagnuolo M, Angileri L, et al. Tavecchio S Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol. 2020. Apr 24. doi: 10.1111/jdv.16527. [Epub ahead of print]
  52. Salinas T, Zheng B, Routy J-P, Ancuta P. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection. Respirology. 2020. Jun; 17:10.1111/resp.13875. doi: 10.1111/resp.13875.
  53. Farooqi F, Dhawan N, Morgan R, Dinh J, Nedd K, Yatzkan G. Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review. Trop Med Infect Dis. 2020. Jul 3; 5(3):E112. doi: 10.3390/tropicalmed5030112.

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 131

PDF (Russian) - 0

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies